The Brigham and Women's Hospital, Inc.

Pfizer Corporation

Children's Medical Center Corporation

Medimmune Limited

Steven A Greenberg

Juan C Almagro

Anthony Coyle

Lidia Mosyak

Edward Roland Lavallie

Brandon Higgs

Stefano V Gulla

Eric M Bennett

Janet Elizabeth Buhlmann

Sreekumar R Kodangattil

Christine Huard

Kenneth Evan Thompson

Yihong Yao

James Perry Hall

Chris Morehouse

Bahija Jallal

Mohammad K Salajegheh

Jame Perry Hall

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

Interferon beta antibodies and uses thereof

A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.

KLRG1 antagonist signaling therapy

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN&#x3b2;). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.

Methods, devices, kits and systems for diagnosing inclusion body myositis (IBM) are provided. Methods, devices, kits and systems involves detecting the presence and/or level of autoantibodies that are reactive against at least a &#x2dc;43 kilodalton (kDa) protein or &#x2dc;43 kDa protein band from a muscle lysate or a mammalian cell lysate, or autoantibodies that are reactive against a cytosolic 5'-nucleotidase 1A protein (NT5C1A), or a cytosolic 5&#x2032;-nucleotidase 1B protein (NT5C1B), or a NT5C1B isoform thereof, or a peptide fragment thereof, an isolated peptide thereof or a fusion protein comprising an isolated peptide of NT5C1A or NT5C1B. Such autoantibodies are only found in IBM patients and not in patients with other myopathies.

Detecting inclusion body myositis

Growing community of inventors

Newton, MA, United States of America

Steven A Greenberg